Literature DB >> 26037622

Successful living-related renal transplantation in a patient with factor H antibody-associated atypical hemolytic uremic syndrome.

Johannes Hofer1, Thomas Giner1, Gerard Cortina1, Therese Jungraithmayr1, Jurate Masalskiene2, Diana Dobiliene2, Renata Mitkiene2, Birute Pundziene2, Sarunas Rudaitis2.   

Abstract

CFH-Ab-associated aHUS requires different diagnostic and therapeutic approaches and then the genetically defined aHUS forms. The risk of post-transplant recurrence with graft dysfunction in CFH-Ab aHUS is not well documented. It is suggested that recurrence can be expected if a significant CFH-Ab load persists at the time of transplantation. A pretransplant procedure to reduce CFH-Ab titer seems reasonable, but accurate recommendations are lacking. Whether further prophylactic interventions after transplantation are necessary has to be decided on an individual basis. We report the case of a late diagnosed CFH-Ab HUS with initial ESRD and a successful living-related renal transplantation over a post-transplant period of four and a half years on the basis of a prophylactic pretransplant IVIG admission.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  atypical HUS; complement factor H antibodies; intravenous immunoglobulins; plasma therapy; renal transplantation

Mesh:

Substances:

Year:  2015        PMID: 26037622     DOI: 10.1111/petr.12519

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  3 in total

Review 1.  Anti-complement-factor H-associated glomerulopathies.

Authors:  Marie-Agnes Dragon Durey; Aditi Sinha; Shambhuprasad Kotresh Togarsimalemath; Arvind Bagga
Journal:  Nat Rev Nephrol       Date:  2016-07-25       Impact factor: 28.314

2.  Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland.

Authors:  Vicky Brocklebank; Sally Johnson; Thomas P Sheerin; Stephen D Marks; Rodney D Gilbert; Kay Tyerman; Meredith Kinoshita; Atif Awan; Amrit Kaur; Nicholas Webb; Shivaram Hegde; Eric Finlay; Maggie Fitzpatrick; Patrick R Walsh; Edwin K S Wong; Caroline Booth; Larissa Kerecuk; Alan D Salama; Mike Almond; Carol Inward; Timothy H Goodship; Neil S Sheerin; Kevin J Marchbank; David Kavanagh
Journal:  Kidney Int       Date:  2017-07-24       Impact factor: 10.612

3.  Early relapse rate determines further relapse risk: results of a 5-year follow-up study on pediatric CFH-Ab HUS.

Authors:  Johannes Hofer; Magdalena Riedl Khursigara; Markus Perl; Thomas Giner; Alejandra Rosales; Gerard Cortina; Siegfied Waldegger; Therese Jungraithmayr; Reinhard Würzner
Journal:  Pediatr Nephrol       Date:  2020-10-07       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.